Revascular Bio selected for AMED drug-development grant
The project targets intractable skin ulcers associated with systemic sclerosis.
Revascular Bio Co., Ltd. has been selected for an AMED drug-discovery ecosystem grant, announced on June 14, 2024. The recipient’s allocation was not disclosed.
The selected project develops a vascular endothelial stem-cell therapy for difficult-to-treat skin ulcers associated with systemic sclerosis. It forms part of AMED’s fourth call for drug-discovery ventures.
The company is developing cell therapies based on academic research into blood-vessel maintenance and regeneration. Its work connects therapeutic research with methods for preparing and manufacturing the cells.
Use of funds
Develop endothelial stem-cell therapy for intractable skin ulcers associated with systemic sclerosis